Telsey Advisory Group Reiterates Outperform on Walmart, Maintains $165 Price Target

Telsey Advisory Group analyst Joseph Feldman reiterates Walmart (NYSE:WMT) with a Outperform and maintains $165 price target.

byBenzinga Newsdesk

February 14, 2023

1 minute read

Telsey Advisory Group analyst Joseph Feldman reiterates Walmart (NYSE:WMT) with a Outperform and maintains $165 price target.

Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO’s Price Target

By Vandana Singh

Today, 9:32 AM

On Monday, REGENXBIO Inc (NASDAQ:RGNX) announced a program update from its ongoing clinical investigation of RGX-314 for wet AMD, a leading cause…

RGNX

Ciena Reports Purchase Of AT&T’s Vyatta Routing, Switching Technology, No Terms Disclosed

By Benzinga Newsdesk

Today, 9:32 AM

Ciena® Corporation (NYSE:CIEN) has entered into a definitive agreement with AT&T to acquire its Vyatta virtual routing and switching technology. The acquisition reflects Ciena’s continued investment in its

CIEN

Applied Molecular Transport Announces Top-line Phase 2 Results From MARKET Combination Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis

By Benzinga Newsdesk

Today, 9:32 AM

– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week

AMTI

Truist Securities Maintains Buy on Malibu Boats, Lowers Price Target to $88

By Benzinga Newsdesk

Today, 9:32 AM

Truist Securities analyst Michael Swartz maintains Malibu Boats (NASDAQ:MBUU) with a Buy and lowers the price target from $95 to $88.

MBUU

Telsey Advisory Group Reiterates Outperform on Walmart, Maintains $165 Price Target

Related Posts

Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO’s Price Target

Ciena Reports Purchase Of AT&T’s Vyatta Routing, Switching Technology, No Terms Disclosed

Applied Molecular Transport Announces Top-line Phase 2 Results From MARKET Combination Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis

Truist Securities Maintains Buy on Malibu Boats, Lowers Price Target to $88